Glioma is the most prevalent primary intracranial tumor, accounting for approximately 30% of all brain and central nervous system tumors and 80% of all malignant brain tumors (Gusyatiner and Hegi, 2018; Xu et al., 2020). According to the current classification by the World Health Organization, gliomas are categorized into four histological grades, which can be further divided into low-grade (Grades I and II) and high-grade (Grades III and IV) tumors. Glioblastoma (GBM) is the most common high-grade glioma, constituting 45.2% of primary malignant brain tumors and central nervous system (CNS) tumors (Louis et al., 2021). GBM is an intractable disease, with a median survival of merely 15 months; only 5.5% of patients survive 5 years after diagnosis. In individuals aged 65 and older, the incidence rate has been shown to rise to 130 cases per million (Kanderi et al., 2024). The pathogenesis of glioma remains elusive; however, two identified risk factors include exposure to high doses of ionizing radiation and high-penetrance genetic mutations associated with rare syndromes. Additionally, carcinogenic factors such as nitrite-containing foods and viral or bacterial infections may also contribute to the development of glioma. The principal clinical manifestations of glioma include increased intracranial pressure, neurological and cognitive dysfunction, and epileptic seizures.

The highly aggressive nature of gliomas and their resistance to traditional treatments present significant challenges for patients. In gliomas, multiple oncogenic factors can create an imbalance between cell proliferation and apoptosis. Researchers are increasingly focusing on individualized treatment plans as their understanding of the biology of gliomas deepens. Among various treatment modalities, the chemotherapy drugs lomustine and temozolomide have garnered considerable attention due to their notable efficacy in glioma treatment. Lomustine is a nitrosourea and an oral alkylating agent. Upon entering the body, lomustine requires hepatic activation to form active intermediates that can modify purine bases in DNA. This modification inhibits DNA, RNA, and protein synthesis, ultimately inducing programmed cell death in rapidly dividing cells (National Institute of Diabetes and Digestive and Kidney Diseases, 2012; Guo et al., 2021). Temozolomide is an alkylating prodrug and a chemotherapeutic agent that can cross the blood-brain barrier. The brain tumor microenvironment is typically alkaline, rendering temozolomide unstable. Temozolomide spontaneously decomposes to form an active metabolite that methylates purine bases in DNA, thereby causing cellular damage and ultimately inducing apoptosis (Zhou et al., 2022; Zhang et al., 2012). Both drugs are extensively utilized in clinical practice for the radiotherapy treatment of tumors. Data from clinical trials have demonstrated that the combination of lomustine and temozolomide is more effective than either drug alone in patients with glioblastoma, resulting in prolonged average survival (Herrlinger et al., 2019). However, despite the achievements of lomustine and temozolomide in clinical settings, their adverse drug reactions (ADRs) (refer to adverse reactions that are directly induced by the drug) must not be overlooked. Adverse reactions not only affect the patient’s treatment experience but may also limit the dosage and efficacy of the drugs, potentially leading to treatment discontinuation. Therefore, a comprehensive and thorough analysis of the adverse reactions associated with these drugs is crucial for optimizing treatment regimens and enhancing treatment safety and tolerability. The existing literature primarily focuses on animal studies, mechanisms of action, and adverse events in small clinical trial samples of lomustine and temozolomide. However, no studies have yet analyzed the combined safety profile of lomustine and temozolomide using large-scale, real-world data. The present study aims to systematically analyze and compare the ADRs related to lomustine and temozolomide as reported in the World Health Organization (WHO) VigiAcess database, with the goal of identifying the antiglioma drug with the lowest risk for individualized use in clinical patients, thereby providing a valuable reference for clinical treatment.

Despite the thoroughness of pre-marketing clinical trials, the safety of these medications remains partially undefined based on data from pre-authorization studies, as these trials are conducted under controlled conditions that differ from everyday practice (Gagliardi et al., 2022). Lomustine and temozolomide, which have been commercially available for a significant period, serve a large patient demographic and have multiple applications. Therefore, it is particularly important and insightful to conduct safety research utilizing extensive data from real-world scenarios. Consequently, a more detailed characterization of ADRs linked to anti-glioma drugs is essential, leveraging spontaneous reports from pharmacovigilance databases. It is noteworthy that there is a lack of comparative studies examining the similarities and disparities in ADRs caused by these drugs. Since 2015, data archived in VigiBase has been made publicly accessible through VigiAccess (Watson et al., 2018; Habarugira and Figueras, 2021).

The VigiAccess database enables searches using the trade names of drugs, while also identifying the active ingredients and presenting the corresponding results of ADR reports. This research primarily examines two anti-glioma drugs used for treating glioma: lomustine and temozolomide. Clinicians frequently need to tailor treatment choices considering the potential risk of adverse events for each patient. To assess the occurrence of adverse reactions associated with these two drugs, we performed a descriptive study that analyzed spontaneously reported adverse reactions in the VigiAccess database and compared the rates of adverse reactions linked to these two medications.

The Spontaneous Reporting System (SRS) is widely employed in pharmacovigilance to assess the safety of suspected adverse events. Clinical trials are subject to limitations, including rigorous designs, stringent enrollment criteria, restricted sample sizes, and short follow-up durations, which may hinder the accurate reflection of real-world scenarios characterized by diverse patient demographics and comorbidities. Consequently, data derived from the SRS database can more effectively illustrate the safety of specific drugs in real-world settings and plays a crucial role in signal detection. Currently, research on the safety signals of numerous drugs primarily relies on three key databases: the EudraVigilance Data Analysis System (EVDAS), the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), and WHO-VigiBase^® (Vogel et al., 2020). In 2015, the WHO introduced WHO-VigiAccess, which provides public access to the information contained in VigiBase^®, the WHO’s global repository of reported potential adverse effects associated with medicinal products. Analyzing data from the WHO-VigiAccess database can reveal previously unknown associations between drugs and AEs, as well as validate some established clinical connections (Yamoah et al., 2022). This study aims to evaluate the post-market adverse events linked to two anti-glioma drugs using the WHO-VigiAccess database.

According to data from WHO-VigiAccess, 62.10% of adverse events related to these two anti-glioma drugs were reported from the Americas, followed by Europe, while Africa reported the lowest incidence of adverse events. Prior research has highlighted a significant issue regarding the low reporting rates of adverse events in both Africa and Oceania (Gidudu et al., 2020; Alawadhi et al., 2012). In South Africa, a shortage of medical understanding concerning biopharmaceuticals among healthcare workers, coupled with high costs and complicated procurement procedures, further exacerbates the challenges associated with the use of these medications (Gidudu et al., 2020; Martelli et al., 2017; Kvamme et al., 2020). The African region has been noted for having the lowest incidence of reported adverse events, which may be attributed to insufficient social mobilization, restricted access to adverse event reporting mechanisms, and low levels of information system coverage.

The number of ADR reports from men (10,100) was approximately equal to that of women (9,980), resulting in a female-to-male ratio of nearly 1:1, which indicates a relatively balanced distribution. When excluding reports lacking information on age, the demographic groups with the highest rates of reported incidents were primarily those aged between 45 and 64 years. An AE)with a reporting rate of 1% or greater is generally considered common (Chen et al., 2019). Major adverse events associated with anti-glioma drugs include life-threatening incidents, disabilities, and congenital malformations. The mortality rates for lomustine and temozolomide are 9.96% and 8.34%, respectively. Lomustine exhibits a higher reporting rate for blood and lymphatic system disorders, gastrointestinal disorders, and hepatobiliary disorders. Conversely, temozolomide has a higher reporting rate for general disorders and administration site conditions, as well as nervous system disorders and skin and subcutaneous tissue disorders. Through the VigiAccess database, we identified the top five adverse reactions related to lomustine: thrombocytopenia (11.35%), vomiting (9.59%), death (9.05%), nausea (6.86%), and leukopenia (6.13%). For temozolomide, the top five adverse reactions are thrombocytopenia (9.40%), death (7.18%), nausea (7.04%), disease progression (6.17%), and vomiting (5.13%). The frequently observed ADRs for both anti-glioma drugs include thrombocytopenia, vomiting, death, nausea, leukopenia, decreased platelet count, neutropenia, disease progression, seizures, fatigue, malignant neoplasm progression, pancytopenia, diarrhea, off-label use, pyrexia, product use in unapproved indications, and drug ineffectiveness.

Lomustine is an emetogenic chemotherapy drug that typically necessitates standard antiemetic precautions, which are generally effective. Thrombocytopenia is the primary toxic reaction associated with this treatment, often leading to dosage reductions, delays in chemotherapy cycles, or even cessation of therapy. Neutropenia and lymphopenia occur less frequently and are generally less severe. Despite this toxic profile, the development of myelodysplastic syndromes and leukemias as sequelae of lomustine chemotherapy is rare. This rarity is presumably due to the limited life expectancy of glioma patients, which decreases the likelihood of complications arising years after exposure to the drug (Czarnywojtek et al., 2023).

The adverse reactions associated with temozolomide are typically classified as NCI common toxicity criteria (CTC) grade 1 or 2 (mild to moderate) and are generally self-limiting. Nausea and vomiting can be effectively managed with antiemetics. The incidence of severe nausea and vomiting (CTC grade 3 or 4) has been reported at 10% and 6%, respectively (Matsuda et al., 2015; Bae et al., 2014). The primary dose-limiting toxicity of temozolomide is myelosuppression, which can occur at any dose but tends to be more pronounced at higher doses (Ortiz et al., 2021). Patients receiving higher doses have experienced adverse reactions such as severe and prolonged myelosuppression, infections, and, in some cases, death. Patients who experience an overdose should have their complete blood counts monitored and receive supportive care as necessary.

Undoubtedly, this study has certain limitations. Firstly, the voluntary nature of the spontaneous reporting system leads to issues such as irregular recording, incorrect reporting, delayed reporting, and incomplete data, all of which complicate data analysis and affect the results. For example, this study lacks data on gender, age, and region, and there is a notable absence of reports from Africa. Therefore, the conclusions and data presented here may not be generalizable to all populations. Secondly, the WHO-VigiAccess database contains cumulative data for drugs since their market introduction, but it does not provide annual ADR data. The 13-year difference in market introduction between the two drugs limits our ability to conduct a more in-depth analysis of the data. In addition, the relatively short life expectancy associated with glioma often precludes the opportunity to observe long-term complications that may arise after several years of drug treatment.

The WHO-VigiAccess database, which operates on a voluntary basis for adverse event reporting, presents several challenges that hinder its ability to provide a complete and thorough count of adverse events. The database may lack essential information regarding reported incidents, highlighting the need to enhance the transparency of reporting practices. By improving the clarity and accessibility of the data available to the public, stakeholders can engage in more effective screening for potential connections between pharmaceuticals and adverse reactions. This enhancement would also help mitigate misguidance that could arise from incomplete or unclear information. The reliance on a spontaneous reporting system carries significant inherent limitations, primarily due to various biases that can affect the reporting process. These biases include notoriety bias, where more well-known drugs receive disproportionate attention, selection bias, which skews the data towards certain demographics, and under-reporting, which typically results in substantial gaps in data collection (Faillie, 2019). In the context of the current study, it was noted that the missing data included adverse events that could not be specifically linked to certain genders or age groups, complicating the interpretation of the data. Additionally, the cumulative nature of the VigiAccess database presents challenges in isolating ADRs on a yearly basis. When medications are introduced to the market at different times, the volume of reported ADRs can vary significantly, complicating efforts to compare signal differences across all drug classes concurrently. Consequently, conducting further data mining becomes impractical. In this analysis, the focus was placed on aggregating the number of ADRs reported over recent years and correlating these with the number of PTs associated with various drugs. This approach was designed to mitigate the impact of the differing timelines of drug market introductions on the study’s outcomes. However, the findings are limited to relative comparisons involving only the two anti-glioma drugs examined in the study.